Journal
VACCINES
Volume 8, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/vaccines8030492
Keywords
flavivirus; mosquito-borne diseases; subunit vaccines
Categories
Funding
- Fundacao Butantan
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [16/20045-7, 18/24683-3, 19/18205-4, 15/02352-7, 16/23560-0]
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [16/23560-0, 19/18205-4, 16/20045-7] Funding Source: FAPESP
Ask authors/readers for more resources
This article aims to review the present status of anti-flavivirus subunit vaccines, both those at the experimental stage and those already available for clinical use. Aspects regarding development of vaccines to Yellow Fever virus, (YFV), Dengue virus (DENV), West Nile virus (WNV), Zika virus (ZIKV), and Japanese encephalitis virus (JEV) are highlighted, with particular emphasis on purified recombinant proteins generated in bacterial cells. Currently licensed anti-flavivirus vaccines are based on inactivated, attenuated, or virus-vector vaccines. However, technological advances in the generation of recombinant antigens with preserved structural and immunological determinants reveal new possibilities for the development of recombinant protein-based vaccine formulations for clinical testing. Furthermore, novel proposals for multi-epitope vaccines and the discovery of new adjuvants and delivery systems that enhance and/or modulate immune responses can pave the way for the development of successful subunit vaccines. Nonetheless, advances in this field require high investments that will probably not raise interest from private pharmaceutical companies and, therefore, will require support by international philanthropic organizations and governments of the countries more severely stricken by these viruses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available